Bivalent Meningococcal B Vaccine Safe, Immunogenic

Share this content:
Bivalent Meningococcal B Vaccine Safe, Immunogenic
Bivalent Meningococcal B Vaccine Safe, Immunogenic

THURSDAY, Dec. 14, 2017 (HealthDay News) -- A bivalent meningococcal B vaccine targeting factor H-binding protein (MenB-FHbp) elicits bactericidal responses against diverse meningococcal B strains after two and three doses in adolescents and young adults, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Lars Ostergaard, M.D., Ph.D., from the Aarhus University Hospital in Denmark, and colleagues assessed the safety and immunogenicity of MenB-FHbp among 3,596 adolescents who were randomized to receive MenB-FHbp or hepatitis A virus vaccine and saline, and 3,304 young adults who were randomized to receive MenB-FHbp or saline at baseline, two months, and six months. Serum bactericidal assays that included human complement (hSBAs) were used to assess immunogenicity.

The researchers found that the percentage of adolescents with an increase in the hSBA titer by a factor of four or more against each primary strain varied from 56.0 to 85.3 percent after dose two and from 78.8 to 90.2 percent after dose three, in the modified intention-to-treat population; for young adults the percentages varied from 54.6 to 85.6 percent after dose two and from 78.9 to 89.7 percent after dose three. After doses two and three, the composite responses were 53.7 and 82.7 percent, respectively, in adolescents, and 63.3 and 84.5 percent, respectively, in young adults.

"We found that MenB-FHbp was safe and immunogenic after dose two and dose three," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the study. Several authors also reported holding patents and having patents pending.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards $4.62B in Johnson & Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »